Eyenovia Announces FDA Acceptance of the MydCombi NDA

NEW YORK--(BUSINESS WIRE)--Mar. 2, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news